![Ira Wallis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Ira Wallis has been Vice President of Regulatory Affairs for Tercica, Inc. since March 2003.
He was Senior Director and Head of Regulatory Affairs for Dynavax Technologies Corporation from May 2001 to January 2003 and a Director and Head of Regulatory Affairs for Cerus Corporation from July 1996 to April 2001.
Dr. Wallis was an Associate Director and Manager of Regulatory Affairs for Genentech, Inc. from 1990 to 1996 and Manager of Regulatory Affairs for Sandoz Pharmaceutical Corporation from 1987 to 1989.
He received a BA degree in Zoology from American International College and a PhD in Neurophysiology from the State University of New York.
Eerdere bekende functies van Ira Wallis
| Bedrijven | Functie | Einde |
|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology Develops new therapeutics for endocrine system disorders | Algemeen Adviseur | 03-02-2014 |
| DYNAVAX TECHNOLOGIES CORPORATION | Algemeen Adviseur | 01-01-2003 |
| CERUS CORPORATION | Directeur/Bestuurslid | 01-04-2001 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Algemeen Adviseur | 01-01-1996 |
Sandoz Pharmaceuticals Corp. | Algemeen Adviseur | 01-01-1989 |
Opleiding van Ira Wallis
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
88
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Cerus Corp.
 Cerus Corp. Medical SpecialtiesHealth Technology Develops and commercializes the INTERCEPT Blood System for platelets and plasma | Health Technology |
Dynavax Technologies Corp.
 Dynavax Technologies Corp. BiotechnologyHealth Technology Develops and commercializes novel products to prevent and treat infectious diseases | Health Technology |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology Develops new therapeutics for endocrine system disorders | Health Technology |
American International College
 American International College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
State University of New York at Buffalo
 State University of New York at Buffalo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sandoz Pharmaceuticals Corp. |
